NPCE
HealthcareNeuroPace, Inc. · Medical - Devices · $580M
What is NeuroPace, Inc.?
NeuroPace is a medical device company focused on treating drug-resistant epilepsy through responsive neurostimulation. Headquartered in Mountain View, California, it serves patients whose seizures have not responded to conventional medication.
NeuroPace develops and commercializes the RNS System, a brain-responsive neuromodulation device implanted at the seizure source. The system continuously records brain activity, detects abnormal patterns, and delivers real-time personalized electrical stimulation to interrupt seizures before they escalate. Clinicians can monitor patients both in person and remotely using the data the device captures. The company sells to hospital facilities that perform both initial implant procedures and replacement procedures.
NeuroPace was incorporated in 1997 and is headquartered in Mountain View, California.
- RNS System — responsive neurostimulation implant for focal epilepsy
- Continuous brain activity recording and long-term data capture
- Remote patient monitoring tools for treating clinicians
- Personalized, real-time seizure detection and therapy delivery
Is NPCE a Good Stock to Buy?
UQS Score rates NPCE as Below Average overall.
The standout pillar for NeuroPace is Growth, which ranks as Strong — reflecting the company's expanding commercial footprint in a niche but underserved market. The Moat and Risk pillars both sit at Neutral, suggesting the RNS System holds a degree of competitive differentiation while operating risks remain manageable relative to peers.
Quality is rated Weak, pointing to profitability and financial efficiency challenges typical of early-commercial medical device companies. Valuation is rated Elevated, meaning the market is pricing in a great deal of future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NPCE pay dividends?
No — NeuroPace, Inc. does not currently pay a dividend.
NeuroPace does not currently pay a dividend. As an early-commercial medical device company, capital is directed toward growing the RNS System's installed base, funding clinical evidence, and expanding its sales infrastructure. Income-focused investors should be aware that a dividend is not part of NeuroPace's current financial strategy.
When does NPCE report earnings?
NeuroPace reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Revenue trends have reflected the company's ongoing commercial ramp, with procedure volumes at hospital facilities serving as a key indicator of business momentum. Profitability remains a work in progress, as is common for medical device companies at this stage of commercialization.
For the most recent quarter's results and guidance, visit NeuroPace's investor relations page directly.
NPCE Price History
-28.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in NeuroPace, Inc.?
Based on NeuroPace, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NPCE Long-term Outlook
NeuroPace's Strong Growth pillar suggests the business is expanding its reach within the medically refractory epilepsy market, which remains significantly underpenetrated. However, the Weak Quality pillar indicates that converting that growth into durable profitability is the central challenge ahead. The Elevated Valuation pillar means the current share price leaves limited room for execution missteps. Investors weighing the long-term opportunity should balance the genuine unmet medical need against the financial and operational hurdles still ahead.
Growth drivers
- Expanding adoption of the RNS System at new hospital centers
- Growing body of long-term clinical outcomes data supporting broader use
- Underpenetrated patient population with drug-resistant focal epilepsy
Key risks
- Sustained losses and weak financial quality metrics pressuring the balance sheet
- Elevated valuation leaving little margin for slower-than-expected growth
- Competitive or reimbursement changes affecting hospital purchasing decisions
NPCE vs Peers
NeuroPace operates in the broader medical technology space alongside other small-cap companies focused on specialized therapeutic and diagnostic devices.
Cytek focuses on flow cytometry instruments and reagents for life science research, operating in a different end market than NeuroPace's implantable neurostimulation devices.
Tactile Systems develops pneumatic compression devices for chronic conditions like lymphedema, sharing NeuroPace's home-care and hospital channel focus but addressing entirely different disease areas.
PacBio develops long-read DNA sequencing platforms for genomics research, making it a technology-driven peer in the healthcare device space with no direct overlap in therapeutic focus.
Frequently Asked Questions
What does NeuroPace do?
NeuroPace develops the RNS System, a brain-responsive neurostimulation device implanted in patients with drug-resistant focal epilepsy. The device continuously monitors brain activity and delivers real-time electrical stimulation at the seizure source. It also enables remote monitoring by treating clinicians, making it a data-driven therapeutic platform.
Does NPCE pay dividends?
No, NeuroPace does not pay a dividend. The company is in a commercial growth phase and reinvests available capital into expanding its RNS System business. Investors seeking dividend income should look elsewhere in the healthcare sector.
When does NPCE report earnings?
NeuroPace reports financial results on a quarterly cadence, as is standard for US-listed companies. Specific dates are not covered by our data source. Check NeuroPace's investor relations page for the current earnings calendar.
Is NPCE a good stock to buy?
UQS Score rates NPCE as Below Average overall. Growth is rated Strong, reflecting commercial momentum, but Quality is Weak and Valuation is Elevated. That combination means investors are paying a premium for a business that has not yet demonstrated consistent financial efficiency. The full pillar breakdown is available to UQS Pro members.
Is NPCE overvalued?
The UQS Valuation pillar for NPCE is rated Elevated, which indicates the current market price reflects high expectations for future growth. For a company still working toward profitability, an elevated valuation leaves limited cushion if commercial execution falls short of expectations.
How does NPCE compare to its competitors?
NeuroPace occupies a narrow but defensible niche in responsive neurostimulation for epilepsy. Peers like Tactile Systems and Cytek Biosciences operate in different therapeutic or research markets. NeuroPace's differentiation lies in its proprietary closed-loop brain stimulation technology, though its financial profile is weaker than many established medical device companies.
What is NPCE's market cap bracket?
NeuroPace is classified as a small-cap company. This reflects its early-commercial stage and relatively limited revenue base compared to large or mega-cap medical device peers. Small-cap stocks in healthcare can carry higher volatility and liquidity risk.
Who founded NeuroPace?
NeuroPace was incorporated in 1997. Founding details are part of the company's publicly available corporate history, which can be found on NeuroPace's official website and SEC filings.
Is NPCE a long-term quality investment?
As a long-term quality indicator, NPCE's UQS profile is mixed. Strong Growth suggests real commercial traction in an underserved market, but Weak Quality and Elevated Valuation are meaningful concerns for long-horizon investors. Sustained improvement in financial efficiency would be a key signal to watch over time.
What is the main competitive advantage of NeuroPace?
NeuroPace's primary advantage is the RNS System's closed-loop design — it detects and responds to abnormal brain activity in real time rather than delivering constant stimulation. This personalized approach, combined with a growing long-term outcomes dataset, creates a degree of clinical differentiation that is difficult for new entrants to replicate quickly.
Is NPCE a growth stock or value stock?
Based on its UQS pillar profile, NPCE leans firmly toward growth. The Growth pillar is rated Strong, while Valuation is rated Elevated — a combination typical of growth-oriented stocks where investors pay a premium for future expansion potential rather than current earnings.
Unlock Full NPCE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and efficiency ratios
- ✓Compare NPCE against sector peers on every pillar
- ✓Track Quality and Valuation changes over time
- ✓Get the full analyst view available only to Pro members
Pro Analysis
NPCE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 24, 2026 | 40.8 | 16.7 | 46.0 | 81.5 | 58.8 | 0.0 | 0.0 |
| Apr 2, 2026 | 40.8 | 16.7 | 46.0 | 81.3 | 58.8 | 0.0 | — |
NPCE — Pillar Breakdown
Quality
— 16.7/100 (25%)NeuroPace, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 81.5/100 (20%)NeuroPace, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 58.8/100 (15%)NeuroPace, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)NeuroPace, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 46/100 (25%)NeuroPace, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NPCE.
Score Composition
Financial Data
More Stock Analysis
How is the NPCE UQS Score Calculated?
The UQS (Unified Quality Score) for NeuroPace, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses NeuroPace, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether NeuroPace, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.